AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 4.14 |
Market Cap | 143.01M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.92 |
PE Ratio (ttm) | -2.44 |
Forward PE | n/a |
Analyst | Buy |
Ask | 5.98 |
Volume | 10,435 |
Avg. Volume (20D) | 37,708 |
Open | 4.83 |
Previous Close | 5.06 |
Day's Range | 4.62 - 4.91 |
52-Week Range | 3.50 - 10.42 |
Beta | undefined |
About TLSI
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular...
Analyst Forecast
According to 6 analyst ratings, the average rating for TLSI stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 134.54% from the latest price.
Next Earnings Release
Analysts project revenue of $8.22M, reflecting a 43.68% YoY growth and earnings per share of -0.31, making a -80.13% decrease YoY.
3 weeks ago · seekingalpha.com
TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are CutTriSalus Life Sciences continues to develop its TriNav infusion system, expanding its reach in liver and pancreatic cancer treatment, despite shifting focus from drug development. TLSI's financials sh...
2 months ago · seekingalpha.com
TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call TranscriptTriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Sz...
2 months ago · businesswire.com
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference CallDENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery t...